Titlebook: Emerging Therapeutic Targets in Ovarian Cancer; Stan Kaye,Robert Brown,Martin Gore Book 2011 Springer Science+Business Media, LLC 2011

表示向前

使入迷

Tumour-Specific Synthetic Lethality: Targeting , Dysfunction in Ovarian Cancer,utation carriers and 10–20% for . carriers The analysis of . and . function in DNA repair is leading to new approaches to antitumour therapy for such patients, including the use of poly(ADP)-ribose polymerase (PARP) inhibitors. Such novel agents are selectively lethal to cells lacking functional . o

脫離

Targeting Inflammatory Pathways in Epithelial Ovarian Cancer,irst-line therapy, attempts at improving survival rates in this setting by combining standard treatment with other cytotoxic agents have only had limited success. In platinum-resistant/refractory disease, single agents have modest activity with an average response rate of 20%. As it appears that a t

Mobile

Epithelial-to-Mesenchymal Transition and Cellular Membrane Receptors in Ovarian Cancer: Moving Forwalignant disease have had varying levels of success in the treatment of patients with ovarian cancer. This chapter will discuss in depth the following cell membrane receptors and proteins: integrins, the EGFR/HER family of receptors, IGF receptors, c-Met, and will mention cadherins and the transform

慎重

高調(diào)

Ovarian Cancer Immunology and Immunotherapy,in its management, new therapies are required in order to improve disease control and survival. The immune system protects us from developing cancer but once ovarian cancer is established, it employs elaborate pathways to circumvent the immune system. Immune suppression in the form of defective anti

cumber

纖細(xì)

,Potential for α-Folate Receptor-Targeted Treatment for Ovarian Cancer,late drugs are largely transported into tumours and normal tissues via the high capacity reduced-folate carrier (RFC). A new generation of antifolates and folate–drug conjugates have been discovered that are preferentially transported via FRs and, because of highly restricted expression in normal ti

掙扎

HARD

https://doi.org/10.1007/978-94-011-2826-1advanced disease with little prospect of cure. The optimal management of epithelial ovarian cancer involves a multidisciplinary approach incorporating surgical staging, cytoreduction, and platinum-based chemotherapy in appropriate patients. There has been little overall change in the incidence and m